133 related articles for article (PubMed ID: 24489840)
1. Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells.
Luevano M; Domogala A; Blundell M; Jackson N; Pedroza-Pacheco I; Derniame S; Escobedo-Cousin M; Querol S; Thrasher A; Madrigal A; Saudemont A
PLoS One; 2014; 9(1):e87086. PubMed ID: 24489840
[TBL] [Abstract][Full Text] [Related]
2. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
[TBL] [Abstract][Full Text] [Related]
3. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential.
Lehmann D; Spanholtz J; Sturtzel C; Tordoir M; Schlechta B; Groenewegen D; Hofer E
PLoS One; 2014; 9(1):e87131. PubMed ID: 24498025
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells.
Lehmann D; Spanholtz J; Osl M; Tordoir M; Lipnik K; Bilban M; Schlechta B; Dolstra H; Hofer E
Stem Cells Dev; 2012 Nov; 21(16):2926-38. PubMed ID: 22571679
[TBL] [Abstract][Full Text] [Related]
5. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR
Erokhina SA; Streltsova MA; Kanevskiy LM; Telford WG; Sapozhnikov AM; Kovalenko EI
Immunol Cell Biol; 2018 Feb; 96(2):212-228. PubMed ID: 29363179
[TBL] [Abstract][Full Text] [Related]
7. In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.
Díaz-Rodríguez Y; Cordeiro P; Belounis A; Herblot S; Duval M
Cancer Immunol Immunother; 2017 Oct; 66(10):1307-1320. PubMed ID: 28555259
[TBL] [Abstract][Full Text] [Related]
8. Development of natural killer cells from hematopoietic stem cells.
Yoon SR; Chung JW; Choi I
Mol Cells; 2007 Aug; 24(1):1-8. PubMed ID: 17846493
[TBL] [Abstract][Full Text] [Related]
9. Role of Chk1 in the differentiation program of hematopoietic stem cells.
Carrassa L; Montelatici E; Lazzari L; Zangrossi S; Simone M; Broggini M; Damia G
Cell Mol Life Sci; 2010 May; 67(10):1713-22. PubMed ID: 20146081
[TBL] [Abstract][Full Text] [Related]
10. Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions
Oyer JL; Croom-Perez TJ; Dieffenthaller TA; Robles-Carillo LD; Gitto SB; Altomare DA; Copik AJ
Front Immunol; 2022; 13():861681. PubMed ID: 35464440
[TBL] [Abstract][Full Text] [Related]
11. Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells.
Mark C; Czerwinski T; Roessner S; Mainka A; Hörsch F; Heublein L; Winterl A; Sanokowski S; Richter S; Bauer N; Angelini TE; Schuler G; Fabry B; Voskens CJ
Nat Commun; 2020 Oct; 11(1):5224. PubMed ID: 33067467
[TBL] [Abstract][Full Text] [Related]
12. 'Off-the-Shelf' Immunotherapy: Manufacture of CD8
Boyd N; Cartledge K; Cao H; Evtimov V; Pupovac A; Trounson A; Boyd R
Cells; 2021 Oct; 10(10):. PubMed ID: 34685611
[TBL] [Abstract][Full Text] [Related]
13. Bystander cells enhance NK cytotoxic efficiency by reducing search time.
Zhou X; Zhao R; Schwarz K; Mangeat M; Schwarz EC; Hamed M; Bogeski I; Helms V; Rieger H; Qu B
Sci Rep; 2017 Mar; 7():44357. PubMed ID: 28287155
[TBL] [Abstract][Full Text] [Related]
14. From stem cell to immune effector: how adhesion, migration, and polarity shape T-cell and natural killer cell lymphocyte development in vitro and in vivo.
Lee BJ; Mace EM
Mol Biol Cell; 2020 May; 31(10):981-991. PubMed ID: 32352896
[TBL] [Abstract][Full Text] [Related]
15. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.
Zhu H; Lai YS; Li Y; Blum RH; Kaufman DS
Stem Cells; 2018 Feb; 36(2):134-145. PubMed ID: 29235195
[TBL] [Abstract][Full Text] [Related]
16. Umbilical cord blood-derived neutrophils possess higher viability than peripheral blood derived neutrophils.
Liu Q; Wu Y; Chen G; Li J; Chen Y; Ge Y; Wang C; Xiong B; Chen D; Wang X; Liu S; Cheng Z
Am J Cancer Res; 2024; 14(3):1190-1203. PubMed ID: 38590402
[TBL] [Abstract][Full Text] [Related]
17. Manufacturing Natural Killer Cells as Medicinal Products.
Chabannon C; Mfarrej B; Guia S; Ugolini S; Devillier R; Blaise D; Vivier E; Calmels B
Front Immunol; 2016; 7():504. PubMed ID: 27895646
[TBL] [Abstract][Full Text] [Related]
18. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
[TBL] [Abstract][Full Text] [Related]
19. A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.
Vasu S; Berg M; Davidson-Moncada J; Tian X; Cullis H; Childs RW
Cytotherapy; 2015 Nov; 17(11):1582-93. PubMed ID: 26432560
[TBL] [Abstract][Full Text] [Related]
20. Umbilical cord blood-derived cellular products for cancer immunotherapy.
Cany J; Dolstra H; Shah N
Cytotherapy; 2015 Jun; 17(6):739-748. PubMed ID: 25795272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
